The Department of Justice (DOJ) recently entered into a settlement with a drug manufacturer regarding the sale and reimbursement of nitroglycerin sustained-release capsules. In this whistleblower-initiated action, there were allegations of false reports to the government regarding the drug's regulatory status and of failing to advise that the drug was no longer qualified for Medicaid coverage, causing false claims to be submitted. The drug had been classified as possibly effective in 1972 under the Drug Efficacy Study Implementation (DESI) program, but then its NDA was proposed for withdrawal in 1999. DOJ termed this "the first False Claims Act agreement with a drug company that sought to charge the government for less than effective drugs." Conceivably, this could presage a new type of action against other products with a complicated regulatory history (DESI, grandfather, etc.).